Found: 15
Select item for more details and to access through your institution.
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. N.PAG, doi. 10.3389/fonc.2020.563249
- By:
- Publication type:
- Article
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2018, v. 37, p. 1, doi. 10.1186/s13046-018-0741-3
- By:
- Publication type:
- Article
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2017, p. 1, doi. 10.1186/s13046-017-0653-7
- By:
- Publication type:
- Article
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 14, p. 5165, doi. 10.3390/ijms21145165
- By:
- Publication type:
- Article
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-49484-4
- By:
- Publication type:
- Article
Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with <i>MET</i> Amplification.
- Published in:
- PLoS ONE, 2013, v. 8, n. 10, p. 1, doi. 10.1371/journal.pone.0078656
- By:
- Publication type:
- Article
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00179
- By:
- Publication type:
- Article
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib.
- Published in:
- Cancers, 2021, v. 13, n. 1, p. 6, doi. 10.3390/cancers13010006
- By:
- Publication type:
- Article
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer.
- Published in:
- Cancers, 2020, v. 12, n. 3, p. 666, doi. 10.3390/cancers12030666
- By:
- Publication type:
- Article
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition.
- Published in:
- Cancers, 2019, v. 11, n. 9, p. 1318, doi. 10.3390/cancers11091318
- By:
- Publication type:
- Article
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2019, v. 38, n. 1, p. N.PAG, doi. 10.1186/s13046-019-1240-x
- By:
- Publication type:
- Article
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
- Published in:
- PLoS ONE, 2015, v. 10, n. 10, p. 1, doi. 10.1371/journal.pone.0141795
- By:
- Publication type:
- Article
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
- Published in:
- Molecular Cancer, 2014, v. 13, n. 1, p. 1, doi. 10.1186/1476-4598-13-143
- By:
- Publication type:
- Article
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
- Published in:
- Molecular Cancer, 2012, v. 11, n. 1, p. 1, doi. 10.1186/1476-4598-11-91
- By:
- Publication type:
- Article